Three-Drug Regimen Bests Chemo in NSCLC.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2021-0380
Abstract: A three-drug regimen containing the CTLA4 inhibitor tremelimumab plus the PD-L1 inhibitor durvalumab and chemotherapy may be an effective first-line treatment strategy for patients with metastatic non-small cell lung cancer. In the phase III POSEIDON… read more here.
Keywords: three drug; drug regimen; chemo nsclc; bests chemo ... See more keywords